73 results about "Corticosterone" patented technology

The invention discloses a clinical-grade serum-free medium for adherent culture of human neural stem cells. The medium disclosed by the invention comprises a basic medium, basic nutrition additives, plant-based human serum albumins, saccharides, lipid, hormones, antioxidants and related substances for promoting metabolism; the basic medium is prepared from commercial DMEM / F12 and a commercial neurobasal medium according to a ratio of 1:1; the basic nutrition additives comprise insulin, holo-transferrin, apo-transferrin, putrescine, progesterone and sodium selenite; the hormones comprise biotin, corticosterone, lipoic acid, Ve and Ve acetic ester; the antioxidants comprise human-derived catalase, human-derived superoxide dismutase, glutathione and Vc; the related substances for promoting metabolism comprise carnitine, T3 and ethanol amine. The medium can improve a cell expansion speed by two to three times, well keeps stem properties of the neural stem cells, keeps the cell differentiation potential of the neural stem cells and eliminates potential animal-origin endotoxin and viral pollution.

An immunoassay apparatus on a chip is disclosed, which can quantitatively measure the concentration of hormones (particularly corticosterone and progesterone) in a biological sample. Such an apparatus can be designed to be used in the field, saving time and money for those taking the measurements. The measurements are made within a micro-fluidic channel configured on a substrate of a chip, which is loaded using simple capillary forces. Competitive immunoassay can be performed, with the competing agents being the hormone (e.g., antigen) and hormone-coated latex beads (e.g., both pre-mixed in a methanol solution).

The invention discloses an improved Neurobasal B27 culture medium. One liter of a Neurobasal culture solution comprises 0.09-0.11 g of biotin, 18-22 micrograms of corticosterone, 1-3 g of L-carnitine, 0.9-1.1 g of linoleic acid, 0.9-1.1 g of ethanol amine, 0.9-1.1 g of linolenic acid, 13-17 g of D(+)-galactose, 6-7 micrograms of progesterone, 15-17 g of putrescine dihydrochloride, 0.08-0.12 g of retinyl acetate, 2.2-2.8 g of thyroid-hormone-removing bovine serum albumin, 0.8-1.5 g of DL-alpha-tocopherol, 2-3 g of catalase, 0.9-1.2 g of DL-alpha-tocopheryl acetate, 0.8-1.3 g of reduced glutathione, 42-52 micrograms of lipoic acid, 2-3 g of superoxide dismutase, 4-6 g of transferring, 3-5 g of human insulin and 0.12-0.16 mg of sodium selenite. The invention further discloses a preparing method and application of the improved Neurobasal B27 culture medium. The improved Neurobasal B27 culture medium can be used for researching the influence of thyroid hormones on the process that embryonic stem cells are differentiated into nerve cells.

The invention provides a qualitative and quantitative detection method of steroid hormones in saliva and particularly relates to a liquid chromatography tandem mass spectrometry detection method of eight steroid hormones in saliva; the steroid hormones include 17-hydroxyprogesterone, progesterone, androstenedione, testosterone, dehydroepiandrosterone, cortisol, corticosterone and aldosterone. Thedetection method herein includes: freezing a human saliva sample, allowing protein precipitation, ultrasonically extracting, filtering, mixing the filtrate with an internal standard liquid, carrying out reversed-phase SPE (solid phase extraction) column purification, and chemically deriving the target products. Full dissolution of the target hormones in saliva is guaranteed; disturbance of impurities in the saliva is eliminated; accuracy and stability are ensured for detection results. The eight hormones are synchronously, qualitatively and quantitatively analyzed by liquid chromatographic separation and mass spectrometric ion-pairing detection. The detection method herein is suitable for synchronous batch detection of hormone molecules having similar structure and approximate chemi-physical properties, has the advantages of high sensitivity, high precision, good repeatability, high detection speed and the like, fully meets the needs of clinical detection, and has high clinical application value.

The invention discloses a solid phase extraction method for various steroid hormones in saliva. The method comprises activating a solid phase extraction column; adding the solid phase extraction column after a sample is processed; rinsing and eluting the solid phase extraction column, and collecting an eluent; adding an organic solvent and uniformly stirring the mixture, performing a centrifugal treatment at room temperature, and then transferring a product to a 96-orifice plate, sealing a film for a test. The solid phase extraction not only removes impurities, but also greatly improves the detection sensitivity and meets the detection requirement of trace steroid hormones in saliva. Compared with other pretreatment methods, the method is easy to operate, saves the solvent, has little impact on the environment, has a short analysis time and high flux, and can complete the test within 7 minutes. The method uses the isotope internal standard method to quantify the steroid hormones at a low detection error. It is verified by a comprehensive methodology that the method can be used for the detection of hydrogenated corticosterone, testosterone and dehydroepiandrosterone in saliva samples and screening of related diseases. The invention also discloses a method for detecting various steroid hormones after solid phase extraction of saliva.

The invention discloses a neural progenitor cell culture medium. The neural progenitor cell culture medium comprises a DMEM / F12 culture medium, human transferrin, recombinant human insulin, progesterone, corticosterone, T3 (Triodo-I-thyronine), glutathione, catalase, superoxide dismutase, vitamin E acetate, tocopherol, linoleic acid, lipoic acid, linolenic acid, L-carnitine hydrochloride, putrescine, ethanolamine hydrochloride, sodium selenite, D-galactose, lactic acid, sodium pyruvate, glutamine, vitamin H, lipidated bovine serum albumin, vitamin C, sodium chloride, dorsomorphin, a basic fibroblast growth factor and insulin. The invention further provides a preparation method for an exosome and application of the exosome. The subcells (acells) of the exosome prepared by using the method have the advantages of being low in cost, safe, free of immunological rejection, capable of penetrating through a blood brain barrier, accurate in target point, simple in treatment means and the like,and the culture medium has a great potential in acellular regeneration medicine.

The invention belongs to the technical field of biotechnology and especially relates to a method for establishing a cell model for diabetes complicated with depression. The method comprises the following steps: adding glucose with a final concentration of 50 to 200 mmol / L and corticosterone with a concentration of 100 to 400 [mu]mol / L into a medium for culturing hippocampal neurons and carrying out intervention culture on the hippocampal neurons for 18 to 24 h so as to obtain the cell model. The cell model is evaluated through general morphological observation, HE dyeing, glucose consumption detection, intracellular neurotransmitter detection, MTT-process detection, flow cytometry, Hoechst fluorescent staining and TUNEL staining; and evaluation results show that the cell model has good effect and can be used for pathological and physiological research on diabetes complicated with depression, research on pathogenesis, in-vitro drug screening or drug evaluation.

An expression cassette, operable in a recombinant host, comprising a heterologous DNA coding sequence encoding a protein, which is functional, alone or in cooperation with one or more additional proteins, of catalyzing an oxidation step in the biological pathway for conversion of cholesterol into hydrocortisone, which step is selected from the group consisting a of: the conversion of cholesterol to pregnenolone; the conversion of pregnenolone to progesterone; the conversion of progesterone to 17alpha-hydroxy-progesterone; the conversion of 17alpha-hydroxyprogesterone to cortexolone; the conversion of cortexolone to hydrocortisone, and the corresponding control sequences effective in said host.

The invention discloses a non-invasive endocrine index for evaluating the thermal comfort of table poultry and application thereof. According to the application, the content of corticosterone in excrement of the table poultry serves as an index to assist evaluation of the thermal comfort of the table poultry. Experiments show that, under the condition that the table poultry are not subjected to interference of changes of external environmental conditions, the content, collected with 2h as a time period, of the corticosterone in the excrement of the table poultry keeps stable at daytime and night, and no large fluctuation exists. However, after the table poultry are suddenly exposed to a high-temperature environment, the content of the corticosterone in the excrement in 2h rises sharply. Therefore, the content of the corticosterone in the excrement of the table poultry in 2h can serve as a non-invasive endocrine index for evaluating the thermal comfort of the table poultry.

The invention discloses a modeling method of a depression animal model of a pubescent mouse. According to the current situation of stay-at-home children in today's society and the pathogenesis mechanism of depression, it is verified through a large number of experiments that a weanling male mouse of a C57BL / 6J strain is raised through a single cage, and the depression animal model of the pubescentmouse is established on the periphery. It is shown through experimental results that the mouse of a model group produces depression-like phenotypes, including animal behaviors, corticosterone and sleeping situation, so that the modeling of the depression animal model of the pubescent mouse succeeds. The model is simple in operation, the current situations of the stay-at-home children can be verywell simulated, and the blank of depression animal models at the key pubescent development stage is also filled. Through the model, the modeling method can be very well used for screening anti-pubescent depression drugs and has the important application value in pathogenesis mechanism of pubescent depression in future.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention discloses a serum substitute for cell culture. Each liter of the serum substitute comprises the following components: 140-165 mg of amino acid, 15-20 mg of asparagine, 15-25 [mu] M of VC, 70-110 [mu] M of vitamin H, 150-200 [mu] M of tocopheryl acetate, 80-120 [mu] M of tocopherol, 10-15 [mu] M of vitamin A, 15-25 g of a bovine pituitary extract, 80-120 [mu] g of an insulin-like growth factor I, 250-350 [mu] g of catalase, 450-550 [mu] M of insulin human recombinant, 5000-10000 [mu] M of human transferrin, 5000000U of superoxide dismutase, 5mM-20mM of corticosterone, 150000-250000mM of D-galactose, 100-150mM of diethanolamine hydrochloride, 49-165mM of glutathione, 80-120mM of l-carnitinechloride, 140.901-161.403mg of inorganic salts and 5-15g of Pluronic F-68.

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

The invention belongs to the technical field of medicinal chemistry, particularly relates to conjugated dialkynediol compounds and an application thereof and aims to provide conjugated dialkynediol compounds having a protection function on nerve cells. The compounds have a protection function on corticosterone injured PC12 cells. The conjugated dialkynediol compounds have the following general structural formula shown in the specification, wherein R1 represents -(CH2)N-, and n ranges from 2 to 8; -CH=CH-(CH2)m-, m ranges from 1 to 8; in -phenyl (CH2)o-(o-, meta-, p-), o ranges from 1 to 8.

Compositions including combinations of β-glucan and Withania somnifera for increasing the immune activity of certain target cytokines and phagocytosis, and reducing cortisol or corticosterone. Methods of improving immunity activity under periods of stress including chronic stress with a combination of β-glucan and Withania somnifera are also described. Particular combinations of β-glucan and Withania somnifera synergistically increases the immune activity of the cytokines IL-12 and IL-6 over expected values.

The invention discloses a preparation method and medicinal application of CHB which is an effective component of bupleurum Chinese and particularly relates to an application of CHB in preparation of a product for treating depression. The CHB which is the effective component of the bupleurum Chinese has a good effect on treating depression caused by various factors, has a certain protection effect on a U251 cell damaged by corticosterone and has the effects of shortening the tail-suspending immobility time and the swimming immobility time of a mouse and improving the decrease of the body temperature of the mouse due to reserpine. Each dose group is significantly and statistically different from the model group, is dose-dependent and has a good antidepressant function.

The invention provides application of atractylenolide in preparation of an antidepressant drug, and relates to the field of medicine. In-vitro activity tests prove that atractylenolide I and atractylenolide III have the better protection activity on corticosterone-damaged PC12 cells, and the mechanism is related to inhibition of neuron apoptosis; in-vivo test results show that atractylenolide I and atractylenolide III can significantly shorten the immobility time of a mouse forced swimming test and a mouse tail suspension test. Experiments prove that atractylenolide I and atractylenolide III have the significant antidepressant effect and can be used for preparing the drug for preventing and treating a depressive disorder.

The invention discloses application of an adenosine compound WS070133 shown as formula I in preparation of products for prevention or treatment of stress disorders. The stress disorders and related diseases include acute stress disorder, posttraumatic stress disorder, adjustment disorder and phobia, anxiety, mania, bipolar disorder and other diseases. Oral administration of WS070133 on posttraumatic stress disorder model animals shows that the adenosine compound has the effects of lowering animal stress level, reducing fear, anxiety like symptoms and learning and memory impairment. Study also shows that WS070133 can lower the corticosterone level and excitatory amino acid content, reduce apoptosis of neurons and has a regulation effect on related protein molecules. WS070133 has the advantages of low toxicity, no dependence, metabolic and addiction, quick metabolic clearance and no residual effect, etc., thus havaing good application and development prospects. (formula I).

The invention belongs to the technical field of biopharmaceutics and provides an application of saikosaponin B2 in preparation of an antidepressant drug. A structural formula of saikosaponin B2 is asshown in the specification, and saikosaponin B2 is a unique active ingredient in the antidepressant drug. In-vitro activity tests prove that saikosaponin B2 has better protection activity for PC12 injured by corticosterone, and in-vivo test results show that saikosaponin B2 can significantly shorten immobile time of mice in forced swimming and tail suspension tests. Test results show that saikosaponin B2 has a significant antidepressant effect and can be used for preparing a drug for preventing and treating depression.

The invention relates to a method for preparing corticosterone electrochemiluminescence sensors on the basis of CdTe-Ag2Se nano-composites and application of the corticosterone electrochemiluminescence sensors, and belongs to the technical field of nano-materials and electrochemical analysis. The corticosterone electrochemiluminescence sensors are prepared from the CdTe-Ag2Se nano-composites with mesoporous silver selenide loaded cadmium telluride quantum dots, and the CdTe-Ag2Se nano-composites are used as corticosterone capture antibody substrate materials. The method and the application have the advantage that corticosterone can be sensitively detected.

The invention relates to a nerve cell serum-free medium and application thereof. The nerve cell serum-free medium comprises the following components: a basic medium D-MEM (Dulbecco's Modified Eagle Medium); growth factors, namely a basic fibroblast growth factor of which the final concentration is 0.1-10mu g / ml, an epidermal growth factor of which the final concentration is 0.1-10mu g / ml, a vascular endothelial growth factor of which the final concentration is 0.1-10mu g / ml, and a brain-derived neurotrophic factor of which the final concentration is 0.01-1mu g / ml; proteins, namely a cattle serum protein of which the final concentration is 0.001-0.1mu g / ml, and transferrin of which the final concentration is 10-500mu g / ml; hormones, namely insulin of which the final concentration is 1-100mu g / ml, an insulin like growth hormone 1 of which the final concentration is 0.1-10mu g / ml, corticosterone of which the final concentration is 1-100mu g / ml, and progesterone of which the final concentration is 0.1-10mu g / ml; and other substances, namely a soybean trypsin inhibitor of which the final concentration is 0.1-20mu g / ml, butanediamine of which the final concentration is 1-100mu g / ml, and sodium selenite of which the final concentration is 1-1000mu g / ml. Compared with the prior art, the invention provides an efficient and reliable serum-free medium for rat nerve cell culture.

The invention provides aquilarotetrol as well as a pharmaceutical composition, a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides the aquilarotetrol (PES-22)as well as the preparation method thereof, and an application of the aquilarotetrol in preparation of medicines for preventing and treating neurodegenerative diseases and depression. The PES-22 has a remarkable protection effect on corticosterone-induced PC12 cell injury, and can be used for preparing a pharmaceutical composition or a dietary supplement composition for preventing and treating depression.

The invention discloses a method for determination of calcium concentration in a rat spinal dorsal horn neuron. The method includes: taking a SD neonatal rat, conducting disinfection and then executing it, separating the spinal dorsal horn tissue, stripping a spinal cord outer membrane, cutting the tissue into small pieces, transferring the pieces into a centrifuge tube, and adding trypsin to conduct digestion; then adding a DMEM / F12 medium containing 10% fetal calf serum to terminate the digestion; conducting blowing to obtain a cell suspension, performing centrifugation and discarding the supernatant; adding an NB / B27 medium to resuspend cells, inoculating the cells into a special laser confocal dish, and performing standing in an incubation box; adding an NB / B27 medium containing penicillin and streptomycin; performing loading with a fluorescent indicator, putting the cells into the incubation box to perform incubation, rinsing the NB medium, then covering the cells with the NB medium, and carrying out scanning detection with a laser scanning confocal microscope. The method for determination of calcium concentration in the rat spinal dorsal horn neuron provided by the invention can be used for observing the influence of corticosterone on the Ca<2+> concentration of the cultured spinal dorsal horn neuron, and creates conditions for studying the regulation of corticosterone on spinal dorsal horn sensory neuron functions and the action mechanism thereof.

An expression cassette, operable in a recombinant host, comprising a heterologous DNA coding sequence encoding a protein, which is functional, alone or in cooperation with one or more additional proteins, of catalyzing an oxidation step in the biological pathway for conversion of cholesterol into hydrocortisone, which step is selected from the group consisting of:the conversion of cholesterol to pregnenolone;the conversion of pregnenolone to progesterone;the conversion of progesterone to 17alpha-hydroxyprogesterone;the conversion of 17alpha-hydroxyprogesterone to cortexolone;the conversion of cortexolone to hydrocortisone, and the corresponding control sequences effective in said host.

The invention discloses hyponicosidesA-D(1-4) separated from Hypericum japonicum, a pharmaceutical composition taking the hyponicosidesA-D(1-4) as an effective component and application of the hyponicosidesA-D(1-4) to preparation of drugs for treating mental diseases. The hyponicosidesA-D(1-4) disclosed by the invention have remarkable protection effects on PC12 cells damaged by induction of corticosterone, so that the hyponicosidesA-D(1-4) have potential for treating mental diseases, preferably treating mental diseases such as depression, senile dementia, anxiety, obsessive-compulsive disorder and schizophrenia of emotional and cognitive impairment.

The invention discloses a synthetic adhering culture medium for cell culture. Each liter of synthetic adhering culture medium is prepared from components as follows: 0.08 g of biotin, 20 mu g of corticosterone, 2 g of L-carnitine, 1.2 g of linoleic acid, 1.2 g of ethanolamine, 0.8 g of linolenic acid, 13-17 g of D-glucose, 5 mu g of progesterone, 1.2 g of sodium pyruvate, 0.08 g of retinyl acetate, 4 g of catalase, 0.9-1.2 g of folic acid, 0.8-1.3 g of reduced glutathione, 60-70 mu g of lipoic acid, 2-3 g of transferrin, 6-8 g of human insulin, 0.1 mg of sodium selenite, 500-600 mL of a banana peel extract, 1.2-2 g of naphthylacetic acid and 0.8-1.5 g of vitamin C. According to the synthetic adhering culture medium for cell culture and a preparation method of the culture medium, no animal serum is contained, the stem cell differentiation culture time is greatly shortened and the experiment cost is saved.